642 related articles for article (PubMed ID: 8941648)
21. Stimulation of protective antibodies against type Ia and Ib group B streptococci by a type Ia polysaccharide-tetanus toxoid conjugate vaccine.
Wessels MR; Paoletti LC; Rodewald AK; Michon F; DiFabio J; Jennings HJ; Kasper DL
Infect Immun; 1993 Nov; 61(11):4760-6. PubMed ID: 8406875
[TBL] [Abstract][Full Text] [Related]
22. Group B Streptococcus type II polysaccharide-tetanus toxoid conjugate vaccine.
Paoletti LC; Wessels MR; Michon F; DiFabio J; Jennings HJ; Kasper DL
Infect Immun; 1992 Oct; 60(10):4009-14. PubMed ID: 1398913
[TBL] [Abstract][Full Text] [Related]
23. Maternal antibody transfer in baboons and mice vaccinated with a group B streptococcal polysaccharide conjugate.
Paoletti LC; Pinel J; Kennedy RC; Kasper DL
J Infect Dis; 2000 Feb; 181(2):653-8. PubMed ID: 10669351
[TBL] [Abstract][Full Text] [Related]
24. Group B streptococcal conjugate vaccines elicit functional antibodies independent of strain O-acetylation.
Pannaraj PS; Edwards MS; Ewing KT; Lewis AL; Rench MA; Baker CJ
Vaccine; 2009 Jul; 27(33):4452-6. PubMed ID: 19490960
[TBL] [Abstract][Full Text] [Related]
25. Maternal group B streptococcal immunization: capsular polysaccharide (CPS)-based vaccines and their implications on prevention.
Palmeiro JK; De Carvalho NS; Botelho AC; Fracalanzza SE; Madeira HM; Dalla-Costa LM
Vaccine; 2011 May; 29(21):3729-30. PubMed ID: 21414381
[TBL] [Abstract][Full Text] [Related]
26. Conjugate vaccines against group B Streptococcus types IV and VII.
Paoletti LC; Kasper DL
J Infect Dis; 2002 Jul; 186(1):123-6. PubMed ID: 12089673
[TBL] [Abstract][Full Text] [Related]
27. Quantitative determination of antibodies to type III group B streptococcal polysaccharide.
Guttormsen HK; Baker CJ; Edwards MS; Paoletti LC; Kasper DL
J Infect Dis; 1996 Jan; 173(1):142-50. PubMed ID: 8537651
[TBL] [Abstract][Full Text] [Related]
28. Immunization of pregnant women with a polysaccharide vaccine of group B streptococcus.
Baker CJ; Rench MA; Edwards MS; Carpenter RJ; Hays BM; Kasper DL
N Engl J Med; 1988 Nov; 319(18):1180-5. PubMed ID: 3050524
[TBL] [Abstract][Full Text] [Related]
29. Recombinant group B Streptococcus alpha-like protein 3 is an effective immunogen and carrier protein.
Yang HH; Mascuch SJ; Madoff LC; Paoletti LC
Clin Vaccine Immunol; 2008 Jul; 15(7):1035-41. PubMed ID: 18463225
[TBL] [Abstract][Full Text] [Related]
30. Effect of pre-existing immunity for systemic and mucosal immune responses to intranasal immunization with group B Streptococcus type III capsular polysaccharide-cholera toxin B subunit conjugate.
Shen X; Lagergård T; Yang Y; Lindblad M; Fredriksson M; Wallerström G; Holmgren J
Vaccine; 2001 May; 19(25-26):3360-8. PubMed ID: 11348699
[TBL] [Abstract][Full Text] [Related]
31. Maternal immunization of mice with group B streptococcal type III polysaccharide-beta C protein conjugate elicits protective antibody to multiple serotypes.
Madoff LC; Paoletti LC; Tai JY; Kasper DL
J Clin Invest; 1994 Jul; 94(1):286-92. PubMed ID: 7518832
[TBL] [Abstract][Full Text] [Related]
32. Group B Streptococcus capsular polysaccharide-cholera toxin B subunit conjugate vaccines prepared by different methods for intranasal immunization.
Shen X; Lagergård T; Yang Y; Lindblad M; Fredriksson M; Holmgren J
Infect Immun; 2001 Jan; 69(1):297-306. PubMed ID: 11119518
[TBL] [Abstract][Full Text] [Related]
33. Induction of cross-reactive antibodies by immunization of healthy adults with types Ia and Ib group B streptococcal polysaccharide-tetanus toxoid conjugate vaccines.
Brigtsen AK; Kasper DL; Baker CJ; Jennings HJ; Guttormsen HK
J Infect Dis; 2002 May; 185(9):1277-84. PubMed ID: 12001045
[TBL] [Abstract][Full Text] [Related]
34. Group B streptococcal type II and III conjugate vaccines: physicochemical properties that influence immunogenicity.
Michon F; Uitz C; Sarkar A; D'Ambra AJ; Laude-Sharp M; Moore S; Fusco PC
Clin Vaccine Immunol; 2006 Aug; 13(8):936-43. PubMed ID: 16893995
[TBL] [Abstract][Full Text] [Related]
35. Type III group B streptococcal polysaccharide induces antibodies that cross-react with Streptococcus pneumoniae type 14.
Guttormsen HK; Baker CJ; Nahm MH; Paoletti LC; Zughaier SM; Edwards MS; Kasper DL
Infect Immun; 2002 Apr; 70(4):1724-38. PubMed ID: 11895934
[TBL] [Abstract][Full Text] [Related]
36. Safety and immunogenicity of an investigational maternal trivalent group B streptococcus vaccine in healthy women and their infants: a randomised phase 1b/2 trial.
Madhi SA; Cutland CL; Jose L; Koen A; Govender N; Wittke F; Olugbosi M; Meulen AS; Baker S; Dull PM; Narasimhan V; Slobod K
Lancet Infect Dis; 2016 Aug; 16(8):923-34. PubMed ID: 27139805
[TBL] [Abstract][Full Text] [Related]
37. Protection against Streptococcus suis Serotype 2 Infection Using a Capsular Polysaccharide Glycoconjugate Vaccine.
Goyette-Desjardins G; Calzas C; Shiao TC; Neubauer A; Kempker J; Roy R; Gottschalk M; Segura M
Infect Immun; 2016 Jul; 84(7):2059-2075. PubMed ID: 27113360
[TBL] [Abstract][Full Text] [Related]
38. The Protective Value of Maternal Group B Streptococcus Antibodies: Quantitative and Functional Analysis of Naturally Acquired Responses to Capsular Polysaccharides and Pilus Proteins in European Maternal Sera.
Fabbrini M; Rigat F; Rinaudo CD; Passalaqua I; Khacheh S; Creti R; Baldassarri L; Carboni F; Anderloni G; Rosini R; Maione D; Grandi G; Telford JL; Margarit I
Clin Infect Dis; 2016 Sep; 63(6):746-753. PubMed ID: 27402816
[TBL] [Abstract][Full Text] [Related]
39. Functional activity of antibodies to the group B polysaccharide of group B streptococci elicited by a polysaccharide-protein conjugate vaccine.
Marques MB; Kasper DL; Shroff A; Michon F; Jennings HJ; Wessels MR
Infect Immun; 1994 May; 62(5):1593-9. PubMed ID: 8168919
[TBL] [Abstract][Full Text] [Related]
40. Glycoconjugate vaccines to prevent group B streptococcal infections.
Paoletti LC; Kasper DL
Expert Opin Biol Ther; 2003 Sep; 3(6):975-84. PubMed ID: 12943456
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]